The objectives of this contract are to conduct Phase 2 and early clinical trials of NCI-sponsored agents, to evaluate biologic effects of these agents on their molecular targets, to evaluate other relevant biologic effects and to determine clinically relevant outcomes/correlates. Major emphasis shall be on Phase 2 studies, pilot protocols that explore promising combination therapies, and high priority studies that are pivotal for drug development and require rapid initiation, completion, and data reporting. The NCI-IND agents to be studied shall include the following: a) Agents developed by the pharmaceutical industry and provided to the NCI for collaborative development;and agents developed by academic investigators and/or the Developmental Therapeutics Program (DTP), DCTD, NCI;b) Agents which have completed some or all Phase I testing, and: c) Combinations of agents for which the individual toxicities are known.

Agency
National Institute of Health (NIH)
Type
Research and Development Contracts (N01)
Project #
261201100099C-4-0-1
Application #
8739507
Study Section
Project Start
2011-09-23
Project End
2014-09-22
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$430,869
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905